autologous dendritic cells

Cell therapyexperimental

Clinical trial activity

79 trials · 73 clinical orgs · 0 marketing orgs

Phase 1
40
Phase 2
46
Phase 3
5
Phase 4
1

Earliest trial started Dec 1, 1996 (NCT00001566)

Timeline

1990s

  1. Jan 1, 1996

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2000

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • Unspecified targetImmunity, passive

    immunity, passive

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • activated dendritic cells
  • ags-003
  • ags-003-bld
  • autologous dendritic cell
  • autologous dendritic cells
  • autologous dendritic cells.
  • autologous dendritic cells generated using gm-csf, interferon alpha and lps
  • autologous mature dendritic cells
  • autologous tolerogenic dendritic cells
  • polarized dendritic cells
  • renal cell carcinoma/cd40l rna-transfected autologous dendritic cell vaccine ags-003

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06342908Phase 1Dec 8, 2024University of California, Los Angeles
NCT06193733Phase 2Feb 19, 2024Chang Gung University
NCT06015269Phase 1Aug 31, 2023Shanghai Cell Therapy Group Co.,Ltd, Shanghai University
NCT05518032Phase 2Feb 1, 2023State University of New York, Buffalo
NCT07202611Phase 2Dec 2, 2022National Taiwan University
NCT05261750Phase 1/Phase 2 (Phase 2)Apr 30, 2022Prodia StemCell Indonesia
NCT05304208Phase 1Nov 2, 2021Erasmus University Rotterdam
NCT05650918Phase 1Aug 30, 2021Erasmus University Rotterdam
NCT05093881N/AAug 24, 2021Pharmicell Co., Ltd., Wonju Christian Hospital
NCT04834544Phase 2Apr 19, 2021Peking University, SOTIO a.s.
NCT04689152Phase 3Mar 2, 2021Pharmicell Co., Ltd., Wonju Christian Hospital
NCT04614051Phase 1Dec 31, 2020Pharmicell Co., Ltd., University of Ulsan
NCT04277221Phase 3Oct 18, 2019Chang Gung University, Safe Save Medical Cell Sciences & Technology Co.,Ltd.
NCT03905902Phase 3Sep 30, 2019Accord Research
NCT04115761Phase 2Jun 6, 2019Ever Supreme Bio Technology Co., Ltd.
NCT03942328Early Phase 1 (Phase 1)May 17, 2019Mayo Clinic, National Cancer Institute (NCI)
NCT03815084Early Phase 1 (Phase 1)Feb 1, 2019Allife Medical Science and Technology Co., Ltd., Henan Medical University, Peking University, The First People's Hospital of Yunan Province
NCT03758625Phase 1Nov 30, 2018National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh
NCT03546426Phase 1Aug 31, 2018Istituto Nazionale per lo Studio e la Cura dei Tumori
NCT03610360Phase 2/Phase 3 (Phase 3)Jun 21, 2018Amphera BV, TMC Pharma
Showing 20 of 79 trials
Page 1 / 4

Organizations

Research & Development (73)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government25231996
Argos TherapeuticsFor profit4422006
Duke UniversityAcademic/Hospital4432000
Hoag Memorial Hospital PresbyterianAcademic/Hospital4212000
University of California, Los AngelesAcademic/Hospital4412000
Chang Gung UniversityAcademic/Hospital3132016
Mayo ClinicAcademic/Hospital3332016
Pharmicell Co., Ltd.For profit3332020
University of BarcelonaAcademic/Hospital3222006
University of PittsburghAcademic/Hospital3322002
Accord ResearchFor profit2222017
Baylor UniversityAcademic/Hospital2222001
Caladrius BiosciencesFor profit2212000
Cedars-Sinai Medical CenterAcademic/Hospital2122007
Clinica Universidad de NavarraAcademic/Hospital2212009
Erasmus University RotterdamAcademic/Hospital2212021
Harvard UniversityAcademic/Hospital2212004
National Institute of Allergy and Infectious Diseases (NIAID)Government2022009
National Institutes of Health (NIH)Government2011996
Peking UniversityAcademic/Hospital2122019
73 organizations
Page 1 / 4